<DOC>
	<DOCNO>NCT00244140</DOCNO>
	<brief_summary>This research study involve use contrast agent call Ultravist Injection . Ultravist , study drug , use improve picture obtain use compute tomography ( CT ) . Ultravist act like dye make CT picture brighter easy read . In case study , inject vein patient 's arm ; , travel blood stream area examine . CT scan take patient 's head and/or body order his/her physician . Phase IIIb Study Document Safety Efficacy Ultravist 370 mg I/ml , When Administered Intravenously , Volumes 162.2 ml , Clinically Indicated Contrast Enhanced Computed Tomography ( CECT ) Head and/or Body</brief_summary>
	<brief_title>Ultravist : Safety Efficacy Computed Tomography Head Body</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. Bayer HealthCare Pharmaceuticals , Inc. sponsor trial .</detailed_description>
	<criteria>Is least 18 year old clinically indicate contrastenhanced CT head body . Patients le 18 year old clinical indication contrastenhanced CT head body .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Ultravist 370</keyword>
	<keyword>CECT</keyword>
	<keyword>CT Scan</keyword>
</DOC>